Category: Policy


Safe and Sound: Balancing Safety with Innovation in American Sunscreens

By Cody R. Barnett, MRA Director of Communications | 10 October 2017 In Allies & Partnerships, Policy, Prevention

Currently, Americans have access to 16 sunscreen active ingredients approved by the Food and Drug Administration (FDA) to prevent skin cancer. The last time a new OTC (Over the Counter) sunscreen ingredient was added to the FDA sunscreen monograph was 1999. Meanwhile, Europeans have access to 29 sunscreen active ingredients. In the United States there are currently eight new sunscreen ingredients that are pending FDA review, which have been used in Europe – many for over ten years. These new, and potentially better, active ingredients could allow sunscreens to last longer and provide better full spectrum coverage that could help us reverse trends of increasing melanoma incidence in this country. Unlike in Europe where sunscreens are classified as cosmetics, in the United States the FDA is required to evaluate all active ingredients in sunscreens as OTC drugs. Meaning, that all U.S. sunscreen ingredients must be found generally recognized as safe and effective (GRASE) in the same manner as other OTC medications. The FDA says that this is critical to keeping us safe, but is it possible to balance innovation and safety?

Read More


Sunscreen Laws may Hinder Protecting Children from Exposure

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In News, Policy, Prevention

With the launch of summer comes conventional discussion around ranking sunscreens, and chatter between the experts to parse what should be considered in choosing the most effective among them. It’s also a key conversation among parents heading into the season with an eye on protecting their children from sun exposure. Yet, something remaining a central concern among those parents is the public policy surrounding use of sunscreen in schools.

Read More


Melanoma Prevention: The Latest Advances & Future Directions

By Pamela Goldsmith, MRA Director of Communications | 28 February 2017 In Events, Policy, Prevention, Science

During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?

Read More


Turning the Tide Against Cancer Through Sustained Medical Innovation

7 October 2014 In Allies & Partnerships, Policy

Guest Blog Contributors Edward Abrahams, Ph.D., President, Personalized Medicine Coalition Margaret Foti, Ph.D., M.D. (h.c.), Chief Executive Officer, American Association for Cancer Research Marcia A. Kean, M.B.A., Chairman, Feinstein Kean Healthcare We live in extraordinary times.

Read More


Partners in Prevention: MRA and The Surgeon General's Call to Action to Prevent Skin Cancer

30 July 2014 In Allies & Partnerships, News, Policy

Two years ago, the Melanoma Research Alliance (MRA) met with Dr. Howard Koh, the Assistant Secretary for Health at the Department of Health and Human Services (HHS), and asked the question that launched a milestone project to elevate melanoma and skin cancer on the agenda for public health: “How can...

Read More



Protecting Melanoma Research Progress in the Midst of Budget Upheaval

By Wendy Selig, MRA President & CEO | 5 December 2013 In Policy

A diagnosis of metastatic melanoma launches individuals and their families into an intense maze of frightening statistics, clinical trials and uncertain prognosis.  Here at the Melanoma Research Alliance (MRA), we are focused on the mission of accelerating the research to bring better options to these patients.

Read More

Login

×